Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

BACKGROUND: The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance, and to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918903/
https://www.ncbi.nlm.nih.gov/pubmed/29695239
http://dx.doi.org/10.1186/s12885-018-4346-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918903/
https://www.ncbi.nlm.nih.gov/pubmed/29695239
http://dx.doi.org/10.1186/s12885-018-4346-1

Ejemplares similares